Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for gastrointestinal diseases. Founded in 2018 and headquartered in Buffalo Grove, Illinois, Phathom Pharmaceuticals possesses exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium-competitive acid blocker (PCAB). This groundbreaking medication inhibits acid secretion in the stomach and has shown significant clinical benefits, providing rapid, potent, and sustained acid suppression.
Phathom's flagship product, VOQUEZNA® (vonoprazan), is now FDA-approved and available in the U.S. for treating Erosive Esophagitis (Erosive GERD) and relieving associated heartburn in adults. VOQUEZNA is the first new class of acid suppression medication approved in the U.S. in over 30 years, offering a novel mechanism of action distinct from other treatments. Its efficacy, demonstrated in clinical trials, surpasses that of traditional proton pump inhibitors (PPIs), showcasing strong healing rates and durable results.
In addition to treating GERD, Phathom is developing vonoprazan for use in combination with antibiotics to treat Helicobacter pylori (H. pylori) infection. VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® are expected to be commercially available soon, providing comprehensive treatment regimens co-packaged with antibiotics.
Phathom Pharmaceuticals is actively engaged in several key initiatives and collaborations. Recent milestones include the U.S. commercial availability of VOQUEZNA, the completion of Phase 3 trials for Non-Erosive GERD, and the amendment of a term loan facility enhancing financial flexibility. Their innovative approach and dedicated national sales force have driven significant market penetration, with VOQUEZNA now estimated to cover 60 million lives through partnerships with major pharmacy benefit managers.
Phathom is committed to addressing unmet medical needs by offering co-pay assistance programs to ensure accessibility and affordability for patients. They continue to explore new treatment options and expand the indications for vonoprazan through ongoing research and development efforts.
For more information, visit the company’s website at www.phathompharma.com, and follow them on LinkedIn and X (formerly Twitter).
Phathom Pharmaceuticals announces FDA approval of VOQUEZNA® (vonoprazan) 10 mg tablets for the relief of heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (GERD) in adults. This marks VOQUEZNA's third FDA approval, following treatments for Erosive Esophagitis and H. pylori infection.
VOQUEZNA represents the first major innovation in GERD treatment in over 30 years, targeting the largest category of GERD affecting an estimated 45 million U.S. adults. In the Phase 3 PHALCON-NERD-301 study, VOQUEZNA demonstrated significant and rapid reduction of heartburn, with 45% heartburn-free days compared to 28% for placebo.
The approval provides a novel treatment option for millions of Non-Erosive GERD patients who remain dissatisfied with current therapies. VOQUEZNA is now available via prescription, with savings programs offered for eligible patients facing coverage or affordability issues.
Phathom Pharmaceuticals (Nasdaq: PHAT) will participate in two key investor conferences in June 2024. The company will present at the Jefferies Global Healthcare Conference in New York on June 5 at 12:30 p.m. ET, and at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach on June 11 at 2:40 p.m. ET. Both events will feature live webcasts and archived recordings available on Phathom's website for 90 days post-conference. Management will also hold one-on-one meetings throughout both conferences.
Phathom Pharmaceuticals will present data on VOQUEZNA® (vonoprazan) at Digestive Disease Week® (DDW) 2024, held from May 18-21 in Washington, D.C. The company will showcase Phase 3 results for Non-Erosive Reflux Disease (NERD) and research on Erosive GERD, shedding light on health care resource utilization and treatment patterns. The U.S. FDA has accepted Phathom's New Drug Application for VOQUEZNA as a daily treatment for heartburn associated with Non-Erosive GERD, with a target action date of July 19, 2024.
Phathom Pharmaceuticals reported net revenues of $1.9 million for the first full quarter of launch, with over 17,500 prescriptions dispensed, representing a 361% increase. Cigna Healthcare added VOQUEZNA tablets to its formularies, broadening coverage to approximately 48% of all U.S. commercial lives. The company is hosting a conference call to discuss the positive progress of VOQUEZNA in treating Erosive GERD. A direct-to-consumer campaign is actively increasing brand awareness, with future clinical trials and expanded indications on the horizon.
Phathom Pharmaceuticals, Inc. will report its first quarter 2024 financial results and provide a business update on Thursday, May 9, 2024. The company, listed on Nasdaq as PHAT, focuses on developing and commercializing novel treatments for gastrointestinal diseases. A live webcast will be hosted at 8:30 am ET on the mentioned date, with access to the presentation available on the company's website.
FAQ
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
What is the market cap of Phathom Pharmaceuticals (PHAT)?
What does Phathom Pharmaceuticals focus on?
What is vonoprazan?
What conditions does VOQUEZNA treat?
What makes VOQUEZNA unique?
Are there other products in development at Phathom?
Where is Phathom Pharmaceuticals headquartered?
When was Phathom Pharmaceuticals incorporated?
What recent financial milestone did Phathom achieve?
How can patients afford VOQUEZNA?
Where can I find more information about Phathom Pharmaceuticals?
